Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Authors
Meyer, TQian, W
Caplin, M
Armstrong, G
Lao-Sirieix, S
Hardy, R
Valle, Juan W
Talbot, D
Cunningham, D
Reed, N
Shaw, A
Navalkissoor, S
Luong, T
Corrie, P
Issue Date
2014-03
Metadata
Show full item recordAbstract
Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an acceptable regimen with or without adding cisplatin.Citation
Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. 2014, 50 (5):902-11 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2013.12.011PubMed ID
24445147Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2013.12.011